()
 
 

Overview

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .


Contact Information

2600 Stemmons Freeway
Suite 176
Dallas, TX 75207

tel: 214-905-5100
fax: 214-905-5101


,  



Investor Relations


Management
tel:
fax:
e-mail:




Stock

Exchange: OTCBB
Industry: Drug Manufacturers - Other
Market Cap: $16.8M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.